• Investors may be wondering whether Cencora at about US$257.71 is offering value right now, or whether the recent volatility is a warning sign.
• The stock has recently been under pressure, with the share price down 1.3% over the last week, down 18.9% over the last month, down 24.0% year to date, while still sitting on a 52.5% gain over three years and 126.0% over five years.
• Recent coverage has focused on Cencora as a major healthcare distributor and services provider, with investors paying closer attention to how sector wide trends could affect its margins and cash flows. Broader discussions around healthcare spending and supply chain resilience have also kept the stock in the spotlight, which helps explain some of the recent share price swings.
• Cencora currently scores 6 out of 6 on Simply Wall St's valuation checks, indicating it screens as undervalued across each metric in that framework. The next step is a closer look at how traditional valuation methods line up and how those compare with an even more complete way to think about what the stock might be worth using Cencora scores just 6/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Cencora Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and discounting them back to today, so that all those future dollars are expressed in current terms.

For Cencora, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $1.66b. Analyst and extrapolated estimates in this model indicate free cash flow in the next decade reaching around $4.38b by 2030, with intermediate annual projections between roughly $3.12b and $4.53b, all in $ terms.

When these projected cash flows are discounted back in this model, the calculation results in an estimated intrinsic value of about $486.69 per share. Compared with a current share price near $257.71, this output suggests the stock screens as around 47.0% undervalued under this DCF framework.

Result: UNDERVALUED (model-based)

Our Discounted Cash Flow (DCF) analysis suggests Cencora is undervalued by 47.0%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Cencora Price vs Earnings

For a profitable company like Cencora, the P/E ratio is a useful yardstick because it links what you pay for the stock to the earnings it is currently generating per share. Investors usually expect higher P/E ratios where they see stronger growth prospects or lower perceived risk, and lower P/E ratios where growth looks more modest or risks are higher.

Cencora currently trades on a P/E of about 19.7x. That sits below the wider Healthcare industry average of roughly 22.4x and below the peer group average of about 25.5x. On the surface, that suggests the stock is priced more conservatively than many Healthcare peers.

Simply Wall St's Fair Ratio for Cencora is 26.9x. This is a proprietary estimate of what the P/E might be given factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it blends these elements into a single figure, the Fair Ratio can be more tailored than a simple comparison with sector or peer averages. With the Fair Ratio above the current 19.7x P/E, this framework indicates the stock screens as undervalued on an earnings multiple basis.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Cencora Narrative

Earlier the article mentioned that there is an even better way to understand valuation. This is where Narratives come in, giving you a simple story behind the numbers in your Cencora view by linking your expectations for future revenue, earnings and margins to a financial forecast, a Fair Value and then a clear comparison with today’s price.

On Simply Wall St’s Community page, Narratives are an accessible tool used by millions of investors that let you align the company’s story with numbers. This helps you see at a glance whether your Fair Value suggests Cencora looks expensive or cheap relative to the current share price and decide for yourself whether that lines up with a buy, hold or sell action.

These Narratives update automatically as new information such as earnings reports or news is incorporated. Cencora already has a range of published views, from a more cautious Narrative that anchors on a Fair Value of about US$280 based on assumptions like 4.5% annual revenue growth and earnings of US$3.4b by 2029 at a 19.9x P/E, to a more optimistic Narrative closer to the analyst consensus Fair Value near US$373 that uses 7.0% revenue growth, earnings of roughly US$3.6b and a 25.0x P/E. This gives you a spectrum of perspectives to benchmark your own assumptions against.

Do you think there's more to the story for Cencora? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.